Cancel Preloader

Epidemiology & Demography

  • Home
  • >
  • Epidemiology & Demography

Researcher

Prof Anthony Scott

Principal Investigator

KEMRI | Wellcome Trust

About

I am a clinical epidemiologist with a specific focus on infectious diseases and vaccines. I trained in clinical medicine at Oxford University, in infectious diseases in London and Newcastle and in epidemiology at the London School of Hygiene & Tropical Medicine (LSHTM). I joined the Programme in 1993 and I was based at the University of Oxford for 15 years before taking up my current position at LSHTM as Professor of Vaccine Epidemiology.

See more

Current Work

My work has explored the aetiology of pneumonia in children and adults, the incidence of bacterial invasive diseases in children and the impact of conjugate vaccines against H. influenzae type b and pneumococcus. I have run trials of different types of vaccines against pneumococcus, in different schedules (e.g. for neonates) and different doses and I have established various systems of public health surveillance against invasive bacterial disease and SARS-CoV-2. With Tom Williams I set up the Kilifi Health and Demographic Surveillance System (KHDSS) in 2000 and I have worked with many internal and external collaborators to estimate cause specific morbidity and mortality in the KDHSS. Research Group - Katherine Gallagher - Wangeci Kagucia - Esther Muthumbi - John Ojal Other Roles; Director of the Health Protection Research Unit in Immunisation, London School of Hygiene & Tropical Medicine Policy roles: Member – Joint Committee on Vaccination and Immunisation (JCVI) UK Member – World Health Organization Strategic Advisory Group of Experts on Immunisation (WHO SAGE)

See more

Recent Publications

View all 110 publications
  1. 2025
    Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project

    Yang, Y. Knoll, M. D. Herbert, et al.

    J Infect. 2025; 90:106426

  2. 2025
    Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis

    Garcia Quesada, M. Peterson, M. E. Bennett, et al.

    Lancet Infect Dis. 2025; 25:445-456

  3. 2025
    Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis

    Bennett, J. C. Deloria Knoll, M. Kagucia, et al.

    Lancet Infect Dis. 2025; 25:457-470

  4. 2024
    Breastfeeding mothers in DR Congo should have access to the mpox vaccine

    Hombach, J. Lewis, R. Holten, et al.

    Lancet Glob Health. 2024; 12:e1932

  5. 2021
    UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records

    Walker, J. L. Grint, D. J. Strongman, et al.

    BMC Public Health. 2021; 21:484